Politics, Policy & Law
Biden hints at executive actions on drug pricing
Biden administration points to Medicare pilot programs, streamlining biosimilar development and possibly march-in rights to cut drug costs
Biden administration points to Medicare pilot programs, streamlining biosimilar development and possibly march-in rights to cut drug costs.
The White House drug pricing plan released Thursday reiterates the administration’s enthusiasm for legislation empowering the government to negotiate drug prices, but the most important news is buried in sections describing options for executive action.
The white paper signals interest in taking actions that do not require legislation, such as streamlining requirements for developing biosimilars, using patent policy to incentivize innovation, and experimenting with new Medicare payment models.
Ambiguous language has cheered proponents and opponents of exercising the government’s “march-in” rights to promote competition for drugs that rely on patents based on government-funded research.
The Comprehensive Plan for Addressing High Drug Prices calls for Congress to enact legislation giving the HHS Secretary power to negotiate Medicare Part D and B drug prices and suggests that